Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790295 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
A Phase 2 study, sponsored by John Mascarenhas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01790295 is a Phase 2 study that was terminated before completion, run by John Mascarenhas. The registered enrollment target is 21 participants.
The verdict
NCT01790295, a Phase 2 study, was terminated before completion, sponsored by John Mascarenhas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells (bone marrow transplantation) will be successful in people who have advanced primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring. This study plans to evaluate whether adding the drug Ruxolitinib will further aid in reducing pre-transplant spleen size, improve physical performance levels and reduce adverse events (side effects) related to the transplant. Ruxolitinib is a drug that is approved by the FDA for the treatment of patients with advanced forms of myelofibrosis. Using Ruxolitinib prior to stem cell transplantation is experimental.
Interventions
- DRUG Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790295
The ClinicalTrials.gov registry entry for NCT01790295 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Mascarenhas, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib Pre- Hematopoietic cell transplantation (HCT) is the first listed.
NCT01790295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01790295 about?
NCT01790295 is a clinical study titled "Ruxolitinib Prior to Transplant in Patients With Myelofibrosis". The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells (bone marrow transplantation) will be successful in people who have advan...
What is the current status of trial NCT01790295?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2013-11. Estimated completion is 2017-10-26.
What interventions are being tested in trial NCT01790295?
The interventions under investigation include: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT) (DRUG).
Who is sponsoring clinical trial NCT01790295?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.